Abstracts tagged "diagnosis and scleroderma"

Abstract Number: 823 • 2015 ACR/ARHP Annual Meeting
Anti-IFI16 Antibodies in Scleroderma Are Associated with Digital Gangrene
Zsuzsanna McMahan¹, Ami A. Shah², Dhananjay Vaidya³, Fredrick M. Wigley⁴, Antony Rosen⁵ and Livia Casciola-Rosen⁶, ¹Rheumatology, Johns Hopkins University, Baltimore, MD, ²Rheumatology, Johns Hopkins University School of Medicine, Baltimore, MD, ³Medicine, School of Medicine, Johns Hopkins, Baltimore, MD, ⁴Rheum Div/Mason F Lord, Johns Hopkins University School of Medicine, Baltimore, MD, ⁵Mason Lord Bldg Ctr Tower, Johns Hopkins University, School of Medicine, Baltimore, MD, ⁶Division of Rheumatology, Johns Hopkins University School of Medicine, Baltimore, MD
Background/Purpose: Our aim was to examine and confirm the association between anti-IFI16 antibodies and clinical features of scleroderma. Methods: Sera from a discovery sample…
Abstract Number: 1730 • 2014 ACR/ARHP Annual Meeting
Identification of Novel Scleroderma –associated Antigens and Development of an Autoantibody Assay Panel Enabling Their Subsequent Validation
Hans-Dieter Zucht¹, Petra Budde¹, Peter Schulz-Knappe¹, Nicolas Hunzelmann², Karsten Conrad³ and Prof. Dr. Matthias Schneider⁴, ¹Protagen AG, Dortmund, Germany, ²Department of Dermatology, University of Cologne, Cologne, Germany, ³Medizinische Fakultät Carl Gustav Carus, Technische Universität Dresden, Dresden, Germany, ⁴Department of Rheumatology, Univ. Duesseldorf, Duesseldorf, Germany
Background/Purpose: Scleroderma (systemic sclerosis or SSc) has a highly variable clinical presentation and course resulting in difficulties for disease management. When SSc is suspected, autoantibodies…
Abstract Number: 2004 • 2012 ACR/ARHP Annual Meeting
Do We Need a Minimum Standards in Care for Children with Localized Scleroderma- Result of the Consensus Meeting in Hamburg Germany On the 11th of December 2011. Part I. Diagnosis and Assessment of the Disease
Ivan Foeldvari¹, Tamás Constantin², Peter Hoeger³, Monika Moll⁴, Clare Pain⁵, Dana Nemcova⁶, Kathryn S. Torok⁷, Lisa Weibel⁸ and Philip J. Clements⁹, ¹Kinder- und Jugenrheumatologie, Hamburger Zentrum Kinder-und Jugendrheumatologie, Hamburg, Germany, ²Pediatric Rheumatology, Semmelweis Egyetem, AOK, II.sz. Gyermekgyogyaszati Klinika, Budapest, Hungary, ³Pediatric Dermatology, Kinderkrankenhaus Wilhelmstift, Hamburg, Germany, ⁴Pediatric Rheumatology, University Childrenxsxhospital, Tübingen, Germany, ⁵Paediatric Rheumatology, Alder Hey Children's Hospital, Liverpool, United Kingdom, ⁶Pediatric Rheumatology, University Childrenxsxhospital, Prague, Czech Republic, ⁷Pediatric Rheumatology, Scleroderma Center of Pittsburgh, Children's Hospital of Pittsburgh of UPMC, Pittsburgh, PA, ⁸Pediatric Dermatology, University Childrenxs Hospital, Zurich, Switzerland, ⁹University of California, Los Angeles, Department of Medicine, Los Angeles, CA
Background/Purpose: Juvenile localised scleroderma (jlSc) is an orphan disease. There are currently no guidelines regarding diagnosis, follow up and treatment. In the frame of the…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].